Kura Oncology Reports First Quarter 2024 Financial Results [Yahoo! Finance]
Kura Oncology, Inc. (KURA)
Last kura oncology, inc. earnings: 2/25 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kuraoncology.com/investor-relations
Company Research
Source: Yahoo! Finance
– Positive preliminary combination data for ziftomenib in NPM1-mutant and KMT2A-rearranged AML – – First patient dosed with KO-2806 and cabozantinib in renal cell carcinoma – – $527 million in cash, cash equivalents and investments provide runway into 2027 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported first quarter 2024 financial results and provided a corporate update. “Ziftomenib continues to demonstrate a best-in-class safety and efficacy profile as well as optimal pharmaceutical properties, which we believe will enable it to become a cornerstone of therapy in acute leukemias and beyond,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. “This belief is backed by increasing investigato
Show less
Read more
Impact Snapshot
Event Time:
KURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KURA alerts
High impacting Kura Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
KURA
News
- Kura Oncology, Inc. (NASDAQ: KURA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $32.00 price target on the stock.MarketBeat
- Kura Oncology, Inc. (NASDAQ: KURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.MarketBeat
- Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML [Yahoo! Finance]Yahoo! Finance
- Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AMLGlobeNewswire
- 2 Incredible Growth Stocks to Buy Hand Over Fist [Yahoo! Finance]Yahoo! Finance
KURA
Earnings
- 5/2/24 - Miss
KURA
Sec Filings
- 5/2/24 - Form SC
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- KURA's page on the SEC website